Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S ADR
(NY:
NVO
)
124.97
-1.19 (-0.94%)
Streaming Delayed Price
Updated: 1:11 PM EDT, Apr 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Novo Nordisk A/S ADR
< Previous
1
2
3
Next >
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
April 22, 2024
The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolio
Via
MarketBeat
MarketBeat Week in Review – 4/15 - 4/19
April 20, 2024
The markets continued to move lower ahead of a big earnings week as analysts adjust valuations on the outlook for interest rates and geopolitical concerns
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Novo Nordisk Arms Wegovy to Be a Triple Threat
April 15, 2024
Novo Nordisk has had success with Ozempic and Wegovy for Type 2 diabetes and obesity, seeks to expand indications to include cardio diseases and neuro disorders
Via
MarketBeat
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
April 09, 2024
Altimmune has a GLP-1 candidate in Phase 2 trials, but the company continues to burn cash and may need a big pharma partner to get its drug to market
Via
MarketBeat
Exposures
Product Safety
Will the Shockwave Medical Deal Be the Jolt JNJ Stock Needs?
April 08, 2024
Johnson & Johnson's proposed acquisition of Shockwave Medical may be the jolt that JNJ stock needs to break out of a year-long downtrend
Via
MarketBeat
Viking Therapeutics Surges Sentiment for Triple Threat GLP-1Pill
April 03, 2024
Viking Therapeutics is preparing to be the next entry into the GLP-1 Market, and VKTX stock is soaring as analysts start to bid the stock higher
Via
MarketBeat
Exposures
Product Safety
DexCom Stock Gains from GLP-1 Diabetic Users
April 02, 2024
DexCom Inc. (NASDAQ: DXCM) is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People
Via
MarketBeat
7 Stocks That Will Drive the Weight Loss Drugs Market
March 28, 2024
The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.
Via
MarketBeat
Nvidia's AI Tech Part of Novo Nordisk's New Supercomputer
March 24, 2024
Novo Nordisk and Nvidia have teamed up to develop supercomputers, aiming to accelerate drug discovery development using advanced AI technologies.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
LifeMD Shares Come Back to Life on GLP-1 Business Growth
March 19, 2024
LifeMD stock is surging as the company is riding the GLP-1 trend to double-digit revenue growth and projections for 67% earnings growth in 2024
Via
MarketBeat
Can WeightWatchers Regain its Mojo after Oprah Steps Down?
March 13, 2024
WW International Inc. (NASDAQ: WW) (WeightWatchers) has had a disastrous 2024, with its shares collapsing 66.7% year-to-date (YTD).
Via
MarketBeat
Are These 5 Undervalued Stocks Ready to Break Out?
March 08, 2024
Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices.
Via
MarketBeat
Vivani Medical Surges on its Ozempic-Like Weight-Loss Implant
March 06, 2024
The Ozempic craze continues to make headlines in the medical sector, and GLP-1 drug stocks such as Vivani Medical continue to surge higher
Via
MarketBeat
Exposures
Product Safety
The Ozempic Diet Trend is Lifting These 2 Carnivore Stocks
March 04, 2024
The carnivore diet is back in the spotlight as people seek GLP-1 alternatives; here are two meat stocks that are moving higher on this trend
Via
MarketBeat
These 2 carnivore dining stocks gaining on the Ozempic craze
February 26, 2024
Ozempic and GLP-1 parallel the artificial intelligence (AI) mania, but it has also propelled "carnivore" restaurants like the two we feature here.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
S&P 500's surge to new highs: Bull trap hiding in plain sight?
February 15, 2024
Nvidia and Meta lead the S&P 500 rally, but there's cause for concern about a potential bull trap amid market volatility and a pivot to stable dividend payers.
Via
MarketBeat
Topics
ETFs
Economy
Stocks
Exposures
Interest Rates
US Equities
5 top healthcare stocks for earnings growth in 2024
January 25, 2024
2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed.
Via
MarketBeat
2 biotechs with promising weight-loss drugs coming
January 16, 2024
Clinical weight-loss medications have been making headlines as GLP-1 drugs like Novo Nordisk A/S (NYSE: NVO) owned Ozempic and Wegovy and Eli Lilly and Co.
Via
MarketBeat
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Looks to Supercharge Reach, Impact of GLP-1 Agonists with Proprietary Drug-Delivery Solution
January 12, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
AstraZeneca: Rebound in 2024 with double-digit earnings growth
January 11, 2024
AstraZeneca's stock rose 8.95% in the past month on a bullish outlook, driven by growing sales of cancer and diabetes drugs and a strategic acquisition
Via
MarketBeat
Exposures
COVID-19
Can Simply Good Foods ride the GLP-1 weight loss trend in 2024?
January 09, 2024
Simply Good Foods may be ready to breakout as the GLP-1 medication weight-loss trend is driving up sales for its Atkins and Quest Nutrition branded products
Via
MarketBeat
Voyager Therapeutics stock pops 30% on deal with Novartis
January 08, 2024
Voyager Therapeutics Inc. (NASDAQ: VYGR) is a biotech in the medical sector that specializes in gene therapy for neurological diseases. Its shares took
Via
MarketBeat
Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs
January 08, 2024
Via
Investor Brand Network
Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs
January 08, 2024
EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:PFE),(NYSE:MRK),(NASDAQ:AZN),(NYSE:NVO) EQNX::TICKER_END
Via
FinancialNewsMedia
2 low-priced gene therapy stocks to speculate on
January 08, 2024
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe
Via
MarketBeat
Exposures
Product Safety
HCA Healthcare Rallies: Weight-loss drugs really a big threat?
January 08, 2024
HCA Healthcare rebounds amid concerns about weight-loss drugs' impact. The healthcare giant's revenue growth hints at resilience despite sector challenges.
Via
MarketBeat
Topics
ETFs
Is the January Effect reliable indicator for yearly performance?
January 04, 2024
The January Effect refers to January’s market return as predictive of the full year. But is January's performance truly an indicator of how the year may go?
Via
MarketBeat
Topics
ETFs
Weight Watchers gains from Oprah’s GLP-1 weight-loss
January 02, 2024
Oprah Winfrey revealed she has lost over 60 pounds and is on the path to reaching her weight goal of 167 lbs. She credits this to taking GLP-1 medication
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
LifeMD expands telehealth GLP-1weight-loss service with Medifast
December 19, 2023
LifeMD Inc. (NASDAQ: LFMD) is a direct-to-consumer (DTC) comprehensive virtual healthcare platform. The company offers per-visit and membership plan pricing
Via
MarketBeat
Can Altimmune's weight-loss drug be a game-changer?
December 14, 2023
The runaway success of weight-loss drugs like Novo Nordisk A/S (NYSE: NVO) Ozempic and Eli Lilly and Co. (NYSE: LLY) Mounjaro has kicked off a gold
Via
MarketBeat
Exposures
Product Safety
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.